December 23, 2025 — Leads & Copy — BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced today its participation in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation scheduled for 7:30 am PST.
The company said live webcasts of these events can be accessed from the investors section of BeOne’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the company’s website.
BeOne Medicines, based in Switzerland, focuses on discovering and developing innovative cancer treatments accessible to patients worldwide. The company’s portfolio covers hematology and solid tumors, and it is expediting the development of its pipeline of novel therapeutics through internal capabilities and collaborations.
The company said it has a global team of nearly 12,000 colleagues across six continents and is committed to improving access to medicines for patients.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Actual results may differ materially from those indicated in the forward-looking statements due to various important factors, which are discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.
Source: BeOne Medicines
